Allurion Technologies WarrantsALUR.WS
About: Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Employees: 137
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
76% more capital invested
Capital invested by funds: $341K [Q3] → $601K (+$261K) [Q4]
9.03% less ownership
Funds ownership: 15.37% [Q3] → 6.35% (-9.03%) [Q4]
14% less funds holding
Funds holding: 44 [Q3] → 38 (-6) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for ALUR.WS.
Financial journalist opinion
We haven’t received any recent news articles for ALUR.WS.